Dr. Jeffrey L. Cummings

Research Professor, Department of Brain Health
Director, Chambers-Grundy Center for Transformative Neuroscience at UNLV
Expertise: Neuroscience, neurodegenerative diseases, Alzheimer’s Disease, drug development, clinical trials, neurotherapeutics


Jeffrey L. Cummings, MD, ScD, joined the UNLV School of Integrated Health Sciences in 2019 as research professor within the department of brain health. Dr. Cummings is the Joy Chambers-Grundy Professor of Brain Science, an endowed professorship. He is the Director of the Chambers-Grundy Center for Transformative Neuroscience, a center devoted to using the tools of neuroscience and neurologic drug development to transform people’s lives.

Prior to UNLV, Dr. Cummings served as founding director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, and as director of the Mary S. Easton Center for Alzheimer’s Disease Research, and director of the Deane F. Johnson Center for Neurotherapeutics, both at UCLA.

A world-renowned Alzheimer’s researcher and leader of clinical trials, Dr. Cummings has been recognized for his scientific and leadership contributions with the American Geriatrics Society’s Henderson Award (2006), the national Alzheimer’s Association’s Ronald and Nancy Reagan Research Award (2008), and the American Association of Geriatric Psychiatry’s Distinguished Scientist Award (2010). 

Dr. Cummings’ interests embrace clinical trials, developing new therapies for brain diseases, and the interface of neuroscience and society. Dr. Cummings has published nearly 800 articles and 44 books devoted to neuroscience, Alzheimer’s disease, and clinical trials.

Dr. Cummings received the Society for Behavioral and Cognitive Neurology’s Lifetime Achievement Award (2017), the International Society of CNS Drug Development’s Leadership and Achievement Award and the national Alzheimer’s Association’s Bengt Winblad Lifetime Achievement Award (2018).

Additionally, he was featured in Gentleman’s Quarterly (June 2009) as a “Rock Star of Science. ™” In addition to his work at UNLV, Dr. Cummings is professor of medicine (Neurology) at Cleveland Clinic Lerner College of Medicine at Case Western Reserve University, and he is principal investigator/director of the National Institute of General Medical Sciences-funded Center for Neurodegeneration and Translational Neuroscience.


  • Sc.D., Science, University of Wyoming
  • Neurology fellowship, Boston University School of Medicine
  • Neuropathology/Neuropsychiatry fellowship, National Hospital for Nervous Diseases, London
  • M.D., Medicine, University of Washington
  • B.S., Zoology/Philosophy, University of Wyoming

Search For Other Experts On

health & medicine, science & technology

Dr. Jeffrey L. Cummings In The News

The FDA has granted both Fast Track and Regenerative Medicine Advanced Therapeutic (RMAT) Designations to Longeveron's Lomecel-B investigational allogeneic medicinal signaling cell (MSC) therapy for the potential treatment of patients with Alzheimer disease (AD).1,2.
Las Vegas Sun
For Dr. Jeffrey Cummings, a brain health researcher and professor at UNLV, this is an exciting time in the fight against Alzheimer’s disease. Federal health advisers in May voted to back an Alzheimer’s drug from Eli Lilly and Co. that can slow the progression of cognitive decline and memory problems. On Tuesday morning the drug — donanemab — gained final approval from the U.S. Food and Drug Administration, making it the second Alzheimer’s drug that slows cognitive decline cleared for use in the United States.
Two new assessments of clinical trials pointed to the need for more investment in Alzheimer's disease treatments. At the 2024 American Geriatrics Societyopens in a new tab or window (AGS) scientific meeting, researchers evaluated Alzheimer's trials funded by the National Institute on Aging (NIA) over a 20-year period. Another analysis, published in Alzheimer's and Dementia: Translational Research and Clinical Interventionsopens in a new tab or window, provided a comprehensive look at active trials in the Alzheimer's drug pipeline.
European Pharmaceutical Review
Considering current developments in Alzheimer’s drugs, a US expert has predicted that the industry should “be prepared for more complex biological therapies that require intravenous infusion and vigilant monitoring for side effects; more like cancer therapies,” according to Dr Jeffrey Cummings, Alzheimer’s clinician-scientist and research professor at the School of Integrated Health Sciences, University of Nevada, Las Vegas.

Articles Featuring Dr. Jeffrey L. Cummings

Josh Hawkins, UNLV
Campus News | July 3, 2024

News highlights featuring UNLV students and staff who made (refreshing) waves in the headlines.

students in spring
Campus News | May 1, 2024

News highlights starring UNLV students and faculty who made local and national headlines.